Head to Head Contrast: PROCEPT BioRobotics (PRCT) vs. Its Rivals

PROCEPT BioRobotics (NASDAQ:PRCT) is one of 511 public companies in the “Healthcare Equipment & Supplies” industry, but how does it weigh in compared to its rivals? We will compare PROCEPT BioRobotics to similar businesses based on the strength of its earnings, risk, dividends, institutional ownership, valuation, analyst recommendations and profitability.

Profitability

This table compares PROCEPT BioRobotics and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
PROCEPT BioRobotics	-32.53%	-30.62%	-22.10%
PROCEPT BioRobotics Competitors	-278.16%	-150.10%	-21.89%

Valuation and Earnings

This table compares PROCEPT BioRobotics and its rivals gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
PROCEPT BioRobotics	$308.05 million	-$95.57 million	-11.16
PROCEPT BioRobotics Competitors	$1.89 billion	$138.79 million	11.28

PROCEPT BioRobotics’ rivals have higher revenue and earnings than PROCEPT BioRobotics. PROCEPT BioRobotics is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Volatility & Risk

PROCEPT BioRobotics has a beta of 0.88, indicating that its stock price is 12% less volatile than the S&P 500. Comparatively, PROCEPT BioRobotics’ rivals have a beta of 2.57, indicating that their average stock price is 157% more volatile than the S&P 500.

Institutional and Insider Ownership

89.5% of PROCEPT BioRobotics shares are owned by institutional investors. Comparatively, 40.5% of shares of all “Healthcare Equipment & Supplies” companies are owned by institutional investors. 4.0% of PROCEPT BioRobotics shares are owned by company insiders. Comparatively, 14.8% of shares of all “Healthcare Equipment & Supplies” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of current ratings and price targets for PROCEPT BioRobotics and its rivals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PROCEPT BioRobotics	2	9	2	3	2.38
PROCEPT BioRobotics Competitors	4266	10507	18257	826	2.46

PROCEPT BioRobotics currently has a consensus price target of $25.50, suggesting a potential upside of 17.73%. As a group, “Healthcare Equipment & Supplies” companies have a potential upside of 16.42%. Given PROCEPT BioRobotics’ higher possible upside, research analysts clearly believe PROCEPT BioRobotics is more favorable than its rivals.

Summary

PROCEPT BioRobotics rivals beat PROCEPT BioRobotics on 7 of the 12 factors compared.

About PROCEPT BioRobotics

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). It also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in San Jose, California.